On November 16, Recursion Pharmaceuticals, Inc. fell 5.34% in Regular Trading, trading at $3.015 per share, with turnover of $11.3909 million.
The clearest catalyst cited in recent market updates is that enthusiasm following the company’s REC-4881 Phase 2 update has continued to fade, with investors shifting back to evaluating the timing and prospects of a registrational trial and the room for valuation recovery.
Recent company disclosures said REC-4881 showed meaningful reductions in polyp burden in familial adenomatous polyposis patients, alongside a relatively clean safety profile that supports advancing toward a registrational study. Separately, the company reported quarterly revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22. The recent pullback suggests the market is weighing clinical promise against execution and timing uncertainty around the next development stage.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments